Published on 13 May 2024 on Simply Wall St. via Yahoo Finance
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the latest downgrade, the three analysts covering Akebia Therapeutics provided consensus estimates of US$165m revenue in 2024, which would reflect a considerable 12% decline on its sales over the past 12 months. Before the latest update, the analysts were foreseeing US$189m of revenue in 2024. The consensus view seems to have become more pessimistic on Akebia Therapeutics, noting the substantial drop in revenue estimates in this update.